Fentanyl vaccine moves closer to human trials
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Victoria Ellis/Axios
Pacific Northwest researchers are closing in on a vaccine that could help prevent fentanyl overdoses by teaching the immune system to stop the drug before it reaches the brain.
Why it matters: Oregon has been hit hard by the fentanyl crisis in recent years. And though overdose deaths involving the drug have fallen since 2024, they remain well above pre-pandemic levels.
- The sheer potency of fentanyl makes it especially dangerous — even a small amount can suppress breathing enough to cause a fatal overdose.
The latest: University of Washington's Pravetoni Research Group is preparing to ask the Food and Drug Administration for permission to begin testing their fentanyl vaccine in human trials, a major step after years of laboratory development, per OPB.
How it works: Because opioid molecules like fentanyl are so small, our immune systems don't notice them in time to create protective antibodies before they reach the brain.
- That's what makes opioids effective painkillers but also what makes them addictive and deadly. Once in the brain, opioids drastically slow activity in the brain and nervous system, causing heavy drowsiness and slowed breathing.
In order to help the brain spot fentanyl, UW researchers created a harmless lookalike — "a copycat molecule" attached to a much larger protein the immune system already detects, chemist Courtney Marecki told OPB.
- This trains the immune system to make antibodies that recognize fentanyl.
- So when the real drug later enters the bloodstream, those antibodies can latch onto it, creating a bundle too big to slip into the brain.
Plus: Early research in preliminary animal trials suggest those manufactured antibodies can reduce cravings and dependency by stopping fentanyl from producing its usual effects in the brain.
- Researchers say vaccine protection can last up to a year.
Yes, but: UW scientists don't see the vaccine as a cure-all for addiction.
- Lab director Marco Pravetoni told OPB he hopes the vaccine could be used alongside medication-assisted treatments including buprenorphine and methadone, as well as behavioral health care.
- Pravetoni also understands most people with substance-use disorder use more than one drug at a time (sometimes without knowing it). That's why his team is also working on a vaccine that tackles multiple substances, too.
What's next: The UW research team's oxycodone vaccine is already in human trials, and its heroin vaccine recently got approval to begin them. The fentanyl vaccine still faces years of human testing and development before it could win final approval.
- Until then, Pravetoni said, the team is keeping a close eye on the illicit drug supply so it can adapt vaccines to other emerging substances, including xylazine.